November 19-21 | Boston, MA, USA

Workshop A: 1 place remaining!

Register by Friday, September 20 to save up to $900!

What’s OnAgenda

7:30 am Registration, Coffee & Networking

8:20 am Chair’s Opening Remarks

ALIGNING INDUSTRY LEADERS AROUND REGULATORY EXPECTATIONS

8:30 am FDA Perspective on Analytical Regulatory Expectations

Synopsis

  • Provide insight in to the type of analytical data required to support agency licensure
  • Present case studies reflective of specific requirements reflective of recent regulatory experience
  • Share the need for adaptation to the specific and unique nature of the gene therapy program – how do expectations differ between indications and scales of manufacturing
  • Review the validation necessary for new technologies – methods, instruments and software
  • Offer insight into the current and future regulatory paradigms for gene therapy manufacturing

9:00 am Presentation Details to be Confirmed

  • Fengrong Zuo Senior Director, CMC, Regulatory, Quality & Analytical Development, AveXis

9:30 am Speed Networking & Morning Refreshments

11:00 am Analytical Methods: A Path to More Efficient Processes & Safer Gene Therapy Products

Synopsis

  • A non-affinity AAV manufacturing process to manage formation of aggregates and result in extra low DNA contaminants will be presented
  • Rapid and sensitive analytics for in-process control of AAV manufacturing with focus on HPLC and different in-line detectors will be shown
  • Qualitative and quantitative information can be obtained in near real-time to assist with process decision-making
  • New ultra-sensitive DNA assay showing major AAV-associated DNA contamination will be introduced

11:30 am Panel Discussion: Evaluating the Analytical Strategies of the Leading Companies in the Field

Synopsis

This interactive panel discussion will bring together the leading companies in the field to discuss key takeaways from pioneering gene therapy programs.

Topics to be covered include:

  • Investigating common analytical challenges encountered across various programs in different indications and with different specifications
  • Balancing the complexities of analytical requirements with the drive to progress therapeutics to market
  • Establishing collaborative relationships with other departments within the organization
  • Lessons learned from the recent approvals of gene therapy products – how has feedback from agencies changed and shaped analytical strategies moving forward?

12:15 pm Lunch & Networking

DEVELOPING EFFECTIVE AND CLINICALLY RELEVANT POTENCY ASSAYS

1:45 pm Potency Assessment for Novel AAV-Based Drugs: Exploration of Different Biological Activities & Stability Indicating Properties of the Assays

Synopsis

  • There are three major types of in-vitro analytical assays for assessment of biological activity of AAV-based therapeutics: infectivity, target protein expression, and functional potency
  • It is important to understand what information each assay can provide and how it can be used for process development and drug characterization
  • Changes in AAV vector structure affect three biological assays in a different manner
  • What strategy can we use if MOA is not clear?

2:15 pm Developing a Potency Assay for GeneRide Products: an AAV-based Genome Editing Platform

  • Lauren Drouin Associate Director, Analytical Development, Logic Bio

Synopsis

  • The Gene Ride platform utilizes the natural process of homologous recombination to achieve targeted genome editing without the use of exogenous nucleases.
  • Current guidance on potency assay development will be discussed, including specific obstacles for gene therapy products.
  • Developing a potency assay for GeneRide vectors demonstrates additional challenges including low levels of integration which requires highly sensitive detection methods. Surrogate methods to investigate biological activity will be described.

2:45 pm Interactive Roundtable Discussions: Deep Dives into Key Existing & Emerging Technologies

Synopsis

Participate in a focussed roundtable discussion to discuss key analytical technologies in an intimate environment. Each table will be led by an industry leader with experience in using the relevant methodology, so this is your opportunity to have your burning questions answered and benchmark your approach with your colleagues in the field. Roundtables will discuss the use of the following approaches

  • qPCR and ddPCR
  • Chromatography
  • Ultracentrifugation
  • Next Generation Sequencing

3:30 pm Afternoon Refreshments & Scientific Poster Session

Synopsis

The scientific poster session is an ideal opportunity to communicate your new results and expertise to a niche audience of industry experts, get feedback from peers and colleagues in the industry and learn how others in the field have been tackling similar challenges.

PIONEERING INNOVATIVE METHODOLOGIES TO EVALUATING CAPSID & GENOME QUALITY

4:00 pm Strategies and Technologies for AAV Genome Characterization

Synopsis

  • Understanding the inherent complexities to AAV genome study
  • Overview of traditional techniques for genome characterization and their limited capacity to meet regulatory requirements
  • Comparison and evaluation of next generation sequencing platforms and their accompanying data analysis

4:30 pm Analytical Ultracentrifugation: A Critical and Versatile Tool to Evaluate Gene Therapy Viral Vectors

  • Qin Zou Associate Research Fellow & Group Leader, Pfizer

Synopsis

  • Analytical Ultracentrifugation is the only tool to provide direct quantification on empty, intermediate and full viral capsids
  • Analytical ultracentrifugation using multi-wavelength detection offer greater confidence in characterizing the particle content
  • Various forms of analytical ultracentrifugation can provide additional information that other separation techniques cannot

5:00 pm AAV Capsid Purity: the Control Strategy & the Evaluation of CE-SDS with LIF Detection

Synopsis

  • Insights into the current strategies and gaps for determining capsid protein purity of AAV gene therapy candidates
  • Providing an overview of novel labeling approaches to enable CE-LIF detection of AAV capsid proteins
  • CE-LIF could be a QC-friendly method for routine monitoring of capsid purity compared with other CE-based analysis

5:30 pm Chair’s Closing Remarks

5:45 pm End of Conference Day One